<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452539</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB_GENDERPED</org_study_id>
    <nct_id>NCT04452539</nct_id>
  </id_info>
  <brief_title>Gender Influence on Morbi-mortality in Pediatric Cardiac Surgery.</brief_title>
  <official_title>Gender Influence on Mortality and Major Morbidity After Pediatric Cardiac Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies show an important influence of gender on inflammatory reactions. Cardiac
      surgery is associated with a major systemic inflammatory response. The investigators want to
      evaluate the gender influence on morbi-mortality in pediatric cardiac surgery patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gender plays an important role in the inflammatory response. This is due to hormonal
      influences, but also different genetic regulation of pro-inflammatory cytokines, as nuclear
      facto kapp B. it is also know that cardiac surgery, especially under cardiopulmonary bypass,
      is associated with a major inflammatory response. This response is even more marked in
      pediatric cardiac surgery. The investigators hypothesise that there is a gender influence on
      mortality and major morbidity in paediatric patients undergoing cardiac surgery. The
      investigators will do a retrospective cohort study, analysing the local database of all
      paediatric cardiac surgery cases from jan 2006 to dec 2019. Primary outcome will be any
      difference in mortality and /or major morbidity according to gender.

      Statistical analysis:

      The investigators will use a propensity score on 11 pre-operative variables clinically judged
      relevant. Both group will be matched until a absolute standardised difference &lt; 15% is
      obtained. This type of matching, contrary to a P value, is independent of sample size.
      Variables will be presented as mean, standard deviation or percentage for frequency
      distributions. After propensity score matching, logistic regressions will be performed on
      binary variables and linear regressions on continuous variables. A Bonferroni correction will
      be used for multiple comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Beginning of the operation until 5 days postop</time_frame>
    <description>Mortality in paediatric cardiac surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Beginning of the operation until 5 days postop</time_frame>
    <description>Major morbidity in paediatric cardiac surgery, defined as at least 2 of the following conditions: Respiratory failure (mechanical ventilation &gt; 90h), prolonged inotropic support (&gt; 5 mcg/kg/min of dobutamine for more than 48h postop), renal insufficiency (Drop in glomerular filtration rate &gt; 75% compared to preop values)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Pediatric Cardiac Surgery</condition>
  <condition>Gender</condition>
  <arm_group>
    <arm_group_label>Paediatric cardiac surgery patients</arm_group_label>
    <description>All patients undergoing paediatric cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paediatric cardiac surgery</intervention_name>
    <description>All patients undergoing paediatric cardiac surgery</description>
    <arm_group_label>Paediatric cardiac surgery patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing paediatric cardiac surgery with cardiopulmonary bypas at our
        institution from jan 2006 to dec 2019.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing paediatric cardiac surgery with cardiopulmonary bypass

        Exclusion Criteria:

          -  Jehova's witness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Denis Schmartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Schmartz, MD</last_name>
    <phone>3224773996</phone>
    <email>denis.schmartz@chu-brugmann.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Van Derlinden, MD</last_name>
    <phone>3224773996</phone>
    <email>philippe.vanderlinden@chu-brugmann.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Universitaire des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Schmartz, MD</last_name>
      <phone>+3224773996</phone>
      <email>denis.schmartz@chu-brugmann.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Denis SCHMARTZ</investigator_full_name>
    <investigator_title>Head, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

